Version 1
: Received: 26 September 2024 / Approved: 27 September 2024 / Online: 27 September 2024 (13:40:48 CEST)
How to cite:
Basavarajappa, B. S.; Subbanna, S. Unveiling the Potential of Phytocannabinoids: Exploring Marijuana's Lesser-Known Constituents for Neurological Disorders. Preprints2024, 2024092224. https://doi.org/10.20944/preprints202409.2224.v1
Basavarajappa, B. S.; Subbanna, S. Unveiling the Potential of Phytocannabinoids: Exploring Marijuana's Lesser-Known Constituents for Neurological Disorders. Preprints 2024, 2024092224. https://doi.org/10.20944/preprints202409.2224.v1
Basavarajappa, B. S.; Subbanna, S. Unveiling the Potential of Phytocannabinoids: Exploring Marijuana's Lesser-Known Constituents for Neurological Disorders. Preprints2024, 2024092224. https://doi.org/10.20944/preprints202409.2224.v1
APA Style
Basavarajappa, B. S., & Subbanna, S. (2024). Unveiling the Potential of Phytocannabinoids: Exploring Marijuana's Lesser-Known Constituents for Neurological Disorders. Preprints. https://doi.org/10.20944/preprints202409.2224.v1
Chicago/Turabian Style
Basavarajappa, B. S. and Shivakumar Subbanna. 2024 "Unveiling the Potential of Phytocannabinoids: Exploring Marijuana's Lesser-Known Constituents for Neurological Disorders" Preprints. https://doi.org/10.20944/preprints202409.2224.v1
Abstract
Cannabis sativa is known for producing over 120 distinct phytocannabinoids, with Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) being the most prominent, primarily in their acidic forms. Beyond Δ9-THC and CBD, a wide array of lesser-known phytocannabinoids, along with terpenes, flavonoids, and alkaloids, demonstrate diverse pharmacological activities, interacting with the endocannabinoid system (eCB) and other biological pathways. These com-pounds, characterized by phenolic structures and hydroxyl groups, possess lipophilic properties, allowing them to cross the blood-brain barrier (BBB) effectively. Notably, their antioxidant, an-ti-inflammatory, and neuro-modulatory effects position them as promising agents in treating neu-rodegenerative disorders. While research has extensively examined the neuropsychiatric and neuroprotective effects of Δ9-THC, other minor phytocannabinoids remain underexplored. Given the well-established neuroprotective potential of CBD, there is growing interest in the therapeutic benefits of non-psychotropic minor phytocannabinoids (NMPs) in brain disorders. This review highlights the emerging research on these lesser-known compounds and their neuroprotective potential. It offers insights into their therapeutic applications across various major neurological conditions.
Keywords
Endocannabinoids; Neurodegenerative disorders; Alcohol use disorders; substance use disorders; Psychiatric disorders; Epilepsy; Cannabinoid receptors; Alzheimer's disease; Parkinson's disease; Huntington's disease
Subject
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
